West Pharmaceutical beats Q3 net sales estimates; lifts FY revenue, EPS outlook
I'm PortAI, I can summarize articles.
West Pharmaceutical Services reported a 7.7% increase in Q3 net sales, surpassing analyst expectations. The company raised its full-year 2025 revenue guidance to $3.060-$3.070 billion and adjusted EPS guidance to $7.06-$7.11. Q4 2025 revenue is projected at $790-$800 million with adjusted EPS of $1.81-$1.86. The average analyst rating is "buy" with a median 12-month price target of $311.00, reflecting a 10.2% upside from the recent closing price of $279.39.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments